A study on the food development for the prevention of the angiogenesis
Project/Area Number |
15K07422
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Food science
|
Research Institution | Tohoku University |
Principal Investigator |
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2017: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 血管新生 / リノレン酸 / エレオステアリン酸 / 共役リノレン酸 / 共役リノール酸 / キリ / ニガウリ / がん / 共役脂肪酸 / マウス / 血管内皮細胞 / HUVEC |
Outline of Final Research Achievements |
In the current study, the antiangiogenic effects of ESA were investigated in vitro. ESA also inhibited the formation of capillary-like networks by human umbilical vein endothelial cells (HUVEC) and moderately inhibited HUVEC proliferation and migration in a dose-dependent manner. The mechanism by which ESA inhibited angiogenesis was through activation of peroxisome proliferator-activated receptor (PPAR) γ and induction of apoptosis in HUVEC. We thus demonstrated that, like troglitazone, ESA is a PPARγ ligand, and that it activates PPARγ induces apoptosis in HUVEC, and inhibits angiogenesis. Our findings suggest that ESA has potential use as a therapeutic dietary supplement and medicine for minimizing tumor angiogenesis.
|
Report
(4 results)
Research Products
(4 results)